Publications by authors named "I E Gokmen"
Article Synopsis
- The study aimed to evaluate how the combination of HALP score and TTCR score influences overall survival (OS) and progression-free survival (PFS) in prostate cancer patients who developed castration resistance.
- A total of 152 metastatic prostate cancer patients were analyzed, categorized based on median cut-off values for HALP (30.83 months) and TTCR (16.1 months), resulting in three risk stratification groups.
- The findings indicated that lower HALP scores and shorter TTCR were linked to significantly worse PFS, and that combining these factors improved predictions for OS and PFS in patients with metastatic castration-resistant prostate cancer (mCRPC).
We evaluated the incidence, clinicopathological features, prognostic factors, progression-free survival (PFS) and overall survival (OS) of patients with gastric cancer and bone metastases. The medical records of 110 patients with bone metastases were retrospectively analyzed. In our study, the incidence of bone metastases was 3.
View Article and Find Full Text PDFMolecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer.
Curr Issues Mol Biol
September 2023
The aim of our study was to evaluate the incidence of KRAS/NRAS and BRAF mutations, analyze molecular patterns, and investigate associations with clinical parameters of these mutations in CRC KRAS/NRAS and BRAF mutations analyzed by next-generation sequencing. The detection rates of these mutations and patients' demographics were recorded and the relationship between them was evaluated using the chi-square test. KRAS mutation was detected in 332 of 694 patients, while the mutation rates in KRAS exons 2/3 and 4 were 39.
View Article and Find Full Text PDFMetastatic castration-resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) in mCRPC patients across multiple cancer centers in Turkey. The study included 165 patients who received at least one cycle of Lu-177 PSMA-617 RLT, with the majority having bone metastases and undergone prior treatments.
View Article and Find Full Text PDFAim: In this study, we aimed to analyze the effect of prognostic nutritional index and neutrophile lymphocyte ratio on the overall survival (OS) in patients treated with regorafenib.
Materials And Methods: Metastatic colorectal cancer (CRC) patients who treated with regorafenib between 2016 and 2020 in a single center were evaluated retrospectively. ROC analysis was used for neutrophile lymphocyte ratio (NLR's) and prognostic nutritional index (PNI's) optimum cut-off value.